Alyeska Investment Group
URGN icon

Alyeska Investment Group’s UroGen Pharma URGN Stock Holding History

Alyeska Investment Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$1.68M – 690
2024
Q2 		$1.68M Buy
+100,000
New +$1.42M 0.01% 426
2017
Q3 		– Sell
-50,000
Closed -$903K – 536
2017
Q2 		$903K Buy
+50,000
New +$868K 0.01% 418

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Alyeska Investment Group's URGN Position: Q3 2024 in Review

Alyeska Investment Group sold out of UroGen Pharma (URGN) in Q3 2024, closing a stake of 100,000 shares — an estimated $1.68M sold.

Alyeska Investment Group first reported a position in URGN in Q2 2017 and held it in 2 quarters. The position peaked at $1.68M in Q2 2024. 128 funds tracked by Wall St. Rank hold URGN as of Q3 2024.

  • Alyeska Investment Group reported no remaining UroGen Pharma position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 100,000 UroGen Pharma shares in Q3 2024, an estimated $1.68M.
  • Alyeska Investment Group first reported a position in UroGen Pharma in Q2 2017 and held it in 2 quarters.
  • Alyeska Investment Group's UroGen Pharma position peaked at $1.68M in Q2 2024.
  • 128 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.